STOCK TITAN

NEOG insider RSU vesting: 9,474 shares issued, 2,085 withheld

Filing Impact
(Neutral)
Filing Sentiment
(Positive)
Form Type
4

Rhea-AI Filing Summary

Neogen Corp (NEOG) insider activity: The company’s Chief Legal Officer reported the vesting and settlement of 9,474 restricted stock units into common stock on 10/27/2025, shown with transaction code M at a stated price of $6.19. A follow-on entry with code F reflects the disposition of 2,085 shares, typically for tax withholding, also at $6.19. After these transactions, the officer directly owned 57,240 shares.

The remarks clarify that each RSU equals one share of common stock and that the RSUs vested on October 27, 2025.

Positive

  • None.

Negative

  • None.

Insights

Routine RSU vesting with tax withholding; neutral impact.

The filing documents a standard equity compensation event: 9,474 RSUs vested and converted to common stock (code M) at a stated price of $6.19 on 10/27/2025. A subsequent line with code F shows 2,085 shares withheld, a common method to satisfy taxes at vesting.

Post-transaction holdings are 57,240 shares directly owned, indicating no open-market sale beyond the tax withholding entry. This is administrative and does not, by itself, indicate a change in outlook or strategy.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Rocklin Amy M

(Last) (First) (Middle)
620 LESHER PLACE

(Street)
LANSING MI 48912

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
NEOGEN CORP [ NEOG ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Legal Officer
3. Date of Earliest Transaction (Month/Day/Year)
10/27/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 10/27/2025 M 9,474 A $6.19 59,325 D
Common Stock 10/27/2025 F 2,085 D $6.19 57,240 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Units $6.19 10/27/2025 M 9,474 10/27/2025 10/27/2025 Common Stock 9,474 $6.19 9,474 D
Explanation of Responses:
Remarks:
Each RSU is the economic equivalent of one share of common stock. On October 27, 2025, these RSUs vested and were settled for an equal number of shares of common stock.
Christopher Sefcheck (Attorney in Fact) 10/28/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did NEOG’s insider report on Form 4?

The Chief Legal Officer reported vesting of 9,474 RSUs on 10/27/2025, converting into common stock (code M) at $6.19.

Were any shares sold by the NEOG insider?

The filing shows 2,085 shares disposed with code F at $6.19, reflecting tax withholding related to the RSU vesting.

How many NEOG shares does the insider hold after the transactions?

The officer directly owns 57,240 shares after the reported transactions.

What does transaction code M mean in this context?

Code M indicates the conversion of a derivative security, here RSUs converting into common stock.

When did the RSUs vest and settle into shares?

The RSUs vested and were settled on October 27, 2025, with each RSU equal to one share of common stock.
Neogen Corp

NASDAQ:NEOG

NEOG Rankings

NEOG Latest News

NEOG Latest SEC Filings

NEOG Stock Data

1.55B
215.36M
0.85%
112.78%
8.46%
Diagnostics & Research
In Vitro & in Vivo Diagnostic Substances
Link
United States
LANSING